ISB News

ISB’s Cancer Genomics Cloud Team Launches BigQuery Platform

Genomeweb published an article on the Cancer Genomics Cloud pilots. Learn more about ISB’s CGC project.

PDF: Cancer Genomics Cloud Pilot Developers Provide Update, Open Up Platforms for Early Testing | GenomeWeb

NEW YORK (GenomeWeb) – The developers of the three proposals selected by the National Cancer Institute for the Cancer Genomics Cloud pilots — an effort to build sustainable computing infrastructure for analyzing omics data from the Cancer Genome Atlas and other NCI-funded projects — have begun various stages of testing ahead of the nine-month evaluation phase of the initiative, which is slated to begin in January 2016 when the first versions of all three platforms will be made available.

The proposals selected for the NCI initiative include one from Seven Bridges Genomics; one from the Institute for System Biology working in collaboration with Google and SRA International; and one from the Broad Institute in partnership with University of California, Berkeley and UC Santa Cruz.

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.